Highlights in bladder cancer at ASCO 2023: NORSE, RAGNAR, and THOR

In this episode, we will be covering highly anticipated updates in urothelial carcinoma presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 in Chicago, IL. We are joined by Arlene Siefker-Radtke, MD of The University of Texas MD Anderson Cancer Center. Professor Siefker-Radtke is a leading expert in genitourinary cancer and will be sharing insights and updates from the ASCO 2023 Annual Congress, including a discussion of the NORSE (NCT03473743), THOR (NCT03390504), and RAGNAR (NCT04083976) trials. These trials investigated the use of the FGFR inhibitor, erdafitinib, in comparison or combination with other therapies.

The post Highlights in bladder cancer at ASCO 2023: NORSE, RAGNAR, and THOR appeared first on VJOncology.